MedTrace Logo

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

NCT02038738 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2014-01-17

No results posted yet for this study

Summary

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.

Conditions

  • Neuroendocrine
  • Neuroendocrine Tumor
  • Neuroendocrine Cancer
  • Neuroendocrine Carcinoma
  • Carcinoid
  • Carcinoid Tumor
  • Islet Cell Tumor
  • Apudoma

Interventions

DRUG

68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.

Sponsors & Collaborators

  • Ochsner Health System

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2019-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038738 on ClinicalTrials.gov